跳至主要内容
临床试验/NCT07425262
NCT07425262尚未招募2 期

A Pilot Randomized Waitlist-controlled Trial of a Zheng-based Chinese Medicine Intervention for Patients With Dialytic Hypotension in Taiwan

Chang Gung Memorial Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年2月2日最近更新:
干预措施

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
100
试验地点
1
主要终点
Total intradialytic hypotension (IDH) epidose

研究概览

简要总结

To evaluate the epidemiological status of traditional Chinese Medicine (TCM) constitution in patients with dialytic hypotension, and design a clinical study based on a Zheng-based herbal formulation to evaluate the clinical efficacy and safety of TCM

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Maintenance bicarbonate hemodialysis (HD) for more than 1 year, three times a week 3.5 to 4.5 h HD schedule.
  • Have experienced more than 30% episodes of IDH (defined as a systolic BP<90 mmHg on dialysis or requirement for clinical intervention) during the exposure assessment period (months 1-3) of this study
  • Cognitive ability to give written informed consent.

排除标准

  • Allergic history to Chinese herbal medicine
  • Systemic diseases such as coagulation disorders, malignancy, liver diseases and cardiovascular diseases.
  • Estimated survival time < 1 year.
  • Mental illness.
  • Participate in other clinical trials.

研究组 & 干预措施

CHM intervention group

Experimental

干预措施: CHM intervention group (Drug)

Control group

Other

Participants who do not receive the active CHM treatment during the study's initial phase (8 weeks) but are offered it after the trial ends.

干预措施: No CHM treatment (Other)

结局指标

主要结局

Total intradialytic hypotension (IDH) epidose

时间窗: week 1 to 8

IDH episode was record on every dialysis session, account for 24 dialysis sessions. ( IDH was defined as a nadir SBP of \< 90 mmHg or requirement for clinical intervention).

次要结局

  • Intradialytic blood pressure (BP) measurement(week 1 to 8)
  • Pharmacotherapy(week 1 to 8)
  • Kidney Disease and Quality of Life-36 (KDQOL-36)(week 1 and 8)

研究者

发起方
Chang Gung Memorial Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ming-Yen Tsai

Head of Chinese medicine

Chang Gung Memorial Hospital

研究点 (1)

Loading locations...

相似试验